American Society of Hirudotherapy

Sylvestin

43-amino-acid contact-kinin pathway inhibitor from forest leech Haemadipsa sylvestris — plasma kallikrein + FXIIa dual blocker; preclinical stroke neuroprotection without bleeding tendency.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Sylvestin4.8 kDa
Molecular weight (kilodaltons) of Sylvestin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

Sylvestin's neuroprotection in rodent ischemic stroke models does NOT establish clinical efficacy in humans. No FDA-approved sylvestin derivative exists. The reported 'no bleeding tendency' result is from animal models only; human bleeding-risk profiles cannot be inferred.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
4,790 Da
Source species
Haemadipsa sylvestris
Discovered
2022 · Zhang Z et al.

Biological Targets

  • → plasma kallikrein
  • → activated Factor XII (FXIIa)

Key Citations

  1. Zhang Z et al. (2022), Cell Mol Life Sci · PMID 35416530

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.